Gut Microbiota in Pulmonary Arterial Hypertension: Murine Models and Human Microbial Signatures, Pathogenic Mechanisms, and Emerging Therapeutic Avenues
Comprehensive Physiology · 2026-02 · 16 (1)
DOI: 10.1002/cph4.70094 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Comprehensive Physiology, online erschienen am 06.01.2026. Verfasst von Yudan Qiu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatric Pulmonology and Immunology, West China Second University Hospital, Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Pulmonary Arterial Hypertension. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 184 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Science and Technology Projects of Xizang Autonomous Region.
Abstract (Originalsprache)
Pulmonary arterial hypertension (PAH) is a chronic, severe cardiopulmonary disease characterized by the progressive increase in pulmonary vascular resistance (PVR) because of the proliferation and fibrosis of the pulmonary arterioles. Although the disease originates in the pulmonary vasculature, it ultimately leads to right heart failure and death. PAH is associated with high mortality rates and poor prognosis, with no therapies currently available to reverse pulmonary vascular remodeling, imposing substantial socioeconomic burdens. Growing interest in the gut–lung axis has highlighted the role of gut microbiota and their metabolites in the occurrence and development of PAH. Evidence showed that gut dysbiosis and metabolite imbalances, involving reduced short‐chain fatty acids (SCFAs), increased trimethylamine‐N‐oxide (TMAO), and dysregulated tryptophan metabolism, contributed to pulmonary vascular remodeling. This review systematically compares gut microbiota and metabolites across PAH murine models (including chronic hypoxia, SU5416/hypoxia [SuHx], monocrotaline [MCT], and non‐classical models) and patients (adults and children). The analysis aims to identify disease‐specific microbial and metabolic signatures. It is also discussed how the microbiota and their metabolites may influence inflammation around the pulmonary vasculature. Furthermore, the potential of probiotic therapy, fecal microbiota transplantation (FMT), and mesenchymal stem cells (MSCs) therapies as novel treatment strategies for PAH is discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pediatric Pulmonology and Immunology, West China Second University Hospital, Sichuan University, Chengdu, China.
- Key Laboratory of Birth Defects and Related Diseases of Women and Children (Sichuan University), Ministry of Education, Chengdu, China.
- The Joint Laboratory for Lung Development and Related Diseases of West China Second University Hospital, Sichuan University and School of Life Sciences of Fudan University, West China Institute of Women and Children's H…
- Department of Pediatrics, Affiliated Hospital of North Sichuan Medical College, Sichuan, China.
- NHC Key Laboratory of Chronobiology (Sichuan University), Chengdu, China.
- Department of Pediatrics, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China.
ORCID-Profile: Yang Liu
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program of China
- Science and Technology Projects of Xizang Autonomous Region
- Sichuan Province Science and Technology Support Program
- Sichuan Provincial Science and Technology Support Program
Zitieren
APA
Qiu, Y., Lyu, X., Zhang, D., Xu, H., He, X., Chen, J., Liu, H., Liu, Y., & Xie, L. (2026). Gut Microbiota in Pulmonary Arterial Hypertension: Murine Models and Human Microbial Signatures, Pathogenic Mechanisms, and Emerging Therapeutic Avenues. Comprehensive Physiology, 16(1). https://doi.org/10.1002/cph4.70094
Vancouver
Qiu Y, Lyu X, Zhang D, Xu H, He X, Chen J, et al. Gut Microbiota in Pulmonary Arterial Hypertension: Murine Models and Human Microbial Signatures, Pathogenic Mechanisms, and Emerging Therapeutic Avenues. Comprehensive Physiology. 2026;16(1). doi:10.1002/cph4.70094
BibTeX
@article{Qiu2026,
author = {Qiu, Yudan and Lyu, Xiaojiang and Zhang, Dashuang and Xu, Hong and He, Xu and Chen, Jiao and Liu, Hanmin and Liu, Yang and Xie, Liang},
title = {Gut Microbiota in Pulmonary Arterial Hypertension: Murine Models and Human Microbial Signatures, Pathogenic Mechanisms, and Emerging Therapeutic Avenues},
journal = {Comprehensive Physiology},
year = {2026},
volume = {16},
number = {1},
doi = {10.1002/cph4.70094}
}
EUVIMED